Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index (HSSCID) has risen by 1.16% as of July 30, 2025, with the Hang Seng Innovative Drug ETF (159316) increasing by 1.91%, marking a three-day consecutive rise [1] - The trading volume for the Hang Seng Innovative Drug ETF (159316) reached 3.80 billion yuan with a turnover rate of 42.92%, indicating active market participation [1] - The Hang Seng Innovative Drug ETF (159316) has seen a cumulative increase of 9.17% over the past week, with its latest scale reaching 855 million yuan and total shares at 528 million, both hitting record highs since inception [1] Group 2 - In Q2 2025, the pharmaceutical sector's public fund holdings have continued to rebound, with a proportion of 7.25% after excluding actively managed pharmaceutical funds, reflecting a 0.9 percentage point increase [2] - The chemical preparation sub-industry saw the largest increase in holdings, rising by 17.5 percentage points, indicating a strong market sentiment towards innovative drugs and related industry chains [2] - The Hang Seng Innovative Drug ETF (159316) is the only ETF product tracking the Hang Seng Innovative Drug Index, providing investors with a unique opportunity to capitalize on the current investment climate in Hong Kong's innovative drug sector [2]